Year: 1996
Type: review
Abstract: Since the discovery of the most potent vasoconstrictor peptide, endothelin, in 1988, explosive investigations have rapidly clarified much of the basic pharmacological, biochemical and molecular biological features of endothelin, including the presence and structure of isopeptides and their genes (endothelin-1, -2 and -3), regulation of gene expression, intracellular processing, specific endothelin converting enzyme (ECE), receptor subtypes (ETA and ETB), intracellular signal transduction following receptor activation, etc. ECE was recently cloned, and its structure was shown to be a single transmembrane protein with a short intracellular N-terminal and a long extracellular C-terminal that contains the catalytic domain and numerous N-glycosylation sites. In addition to acute contractile or secretory actions, endothelin has been shown to exert long-term proliferative actions on many cell types. In this case, intracellular signal transduction appears to converge to activation of mitogen-activated protein kinase. As a recent dramatic advance, a number of non-peptide and orally active receptor antagonists have been developed. They, as well as current peptide antagonists, markedly accelerated the pace of investigations into the true pathophysiological roles of endogenous endothelin-1 in mature animals; e.g., hypertension, pulmonary hypertension, acute renal failure, cerebral vasospasm, vascular thickening, cardiac hypertrophy, chronic heart failure, etc. Thus, the interference with the endothelin pathway by either ECE-inhibition or receptor blockade may provide an exciting prospect for the development of novel therapeutic drugs.
DOI: 10.1254/jjp.72.261
Institution: University of Tsukuba
Language: English
Subfield: Physiology (medical)
Field: Medicine
Domain: Health Sciences
Keywords: endothelin, endothelin-1, endothelin-2, endothelin-3, endothelin-converting enzyme, ETA receptor, endothelin B receptor, signal transduction, mitogen-activated protein kinase, receptor antagonists, vasoconstriction, hypertension, pulmonary hypertension, acute kidney injury, cerebral vasospasm, cardiac hypertrophy, chronic heart failure, gene expression regulation
Open Access status: diamond
Funder: University of Tsukuba
OpenAlex ID: W2038113052
